Supporting Drug Developers in Making Real-World Evidence-based Decisions. From Clinical
Development to Commercialisation
Today more than ever, real-world data collected from mobile, digital and AI technologies are used to help drug developers in generating more value-based outcomes in the development and accessibility of new treatments.
To gain competitive advantage and achieve better outcomes, pharma and biotech organizations seek to advance the way they use RWE - real-world evidence, for the benefit of patients and the commercial success of their products.
If you’re interested to find out more about this paradigm transformation in product lifecycle – from drug development to commercialization - join the 6th annual IMPACCT: RWE, where over 60 leading pioneers from key stakeholders in this space will gather to support the effective leverage of RWE in pursuit of more evidence-based decision making across the drug development continuum.
Share your perspectives and lessons learned with a senior community of industry peers actively involved in the clinical and commercial application of real-world evidence
Discover how to innovate the use of the available real-world data, and translate it into clinically meaningful effects and more evidence-based decision-making processes.
Gain insight into how to plan the evidence generation to effectively support drug development and commercialization success.
Contribute to collaboratively advance the ‘impacct’ of RWE in drug development, patient-centricity, and product life-cycle.
View the full event program for IMPACCT: RWE 2018 with a detailed agenda, workshop details, expert speaker line-up, 18+ focused case studies and attendance breakdown.
Vice President, US
HEOR & RWE
VP Market Access - Global Strategy & US
(former VP & Head of HEOR, EMD Serono)- Managing Partner
Global Head of Real World Data Science Analyticse)
How can RWE Truly ‘Impacct’ Drug Development & Life Cycle Management?
Addressing the growing importance of real-world evidence in pharmaceutical decision-making in product development and commercialization – are we on the verge of a transformation in how we evaluate medicines?
Optimizing Pricing & Market Access Potentials with Evidence Generation
Discover how organizations are tackling RWE generation approaches to support market access activities. Explore what kind of evidence is needed at each stage to optimize pricing and reimbursement potential.
Understanding the RWE Value Lever: Changing Decisions
Explore opportunities and strategies for RWE to use decision science as a vehicle to achieve greater value by informing and helping to change drug development and commercial decision making.
"Well organized, conference host was very nice and helpful, can't wait to speak again and network with colleagues again"
"Excellent line-up of topics and a great gathering of true experts in the field of RWE. Well done Hanson Wade."
"Well organised event with a focused audience. The organisers were able to bring together individuals from different industries who despite their diverse backgrounds had a deep, shared interest in the topic."
AVAILABLE GROUP DISCOUNTS:
Book a Team of 2 - Save an Additional 10% Off
Book a Team of 3 - Save an Additional 10% Off
Book a Team of 4+ - Save an Additional 20% Off